Bio Medica Laboratories IPO Launch: Key Details and Market Sentiment
Bio Medica Laboratories IPO: Check GMP, price band, subscription and other details
The Economic Times
Image: The Economic Times
Bio Medica Laboratories' initial public offering (IPO) opens for subscription on May 21, aiming to raise approximately ₹52.43 crore ($6.3 million USD). The price band is set between ₹132-139 per share, with a grey market premium indicating muted investor sentiment. The IPO closes on May 25, with shares expected to list on May 29.
- 01The IPO consists of a fresh issue of 33.95 lakh shares worth around ₹47.19 crore ($5.7 million USD) and an offer for sale of 3.77 lakh shares valued at ₹5.24 crore ($630,000 USD).
- 02Retail investors must apply for a minimum of 2,000 shares, equating to a minimum investment of ₹2.78 lakh ($3,350 USD) at the upper price band.
- 03The company, established in 2015, specializes in manufacturing pharmaceutical parenteral formulations, including injectable drugs for human and veterinary healthcare.
- 04Bio Medica Laboratories currently offers 58 liquid injectable products and 15 dry powder injectable products, catering to hospitals and pharmaceutical distributors.
- 05Proceeds from the IPO will be allocated for working capital, capital expenditure, and general corporate purposes.
Advertisement
In-Article Ad
Bio Medica Laboratories is set to launch its initial public offering (IPO) for subscription from May 21 to May 25, with shares tentatively scheduled to list on the NSE SME platform on May 29. The IPO aims to raise approximately ₹52.43 crore (around $6.3 million USD) through a combination of a fresh issue and an offer for sale. The price band is fixed at ₹132-139 per share, but grey market activity indicates a 0% premium, reflecting muted sentiment among investors. The IPO includes a fresh issue of 33.95 lakh shares worth about ₹47.19 crore and an offer for sale of 3.77 lakh shares valued at approximately ₹5.24 crore. Retail investors are required to apply for a minimum of 2,000 shares, translating to an investment of ₹2.78 lakh (around $3,350 USD) at the upper end of the price band. Established in 2015, Bio Medica Laboratories manufactures a range of injectable drugs for both human and veterinary healthcare, with a diverse product portfolio. The proceeds will primarily support working capital needs and capital expenditures.
Advertisement
In-Article Ad
The IPO's success could influence the availability of funds for Bio Medica Laboratories, potentially leading to increased production capacity and product offerings, which may benefit healthcare providers and patients.
Advertisement
In-Article Ad
Reader Poll
Are you planning to invest in the Bio Medica Laboratories IPO?
Connecting to poll...
Read the original article
Visit the source for the complete story.